Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
In the latest session, CytomX Therapeutics Inc (NASDAQ: CTMX) closed at $2.17 down -8.44% from its previous closing price of $2.37. In other words, the price has decreased by -$8.44 from its previous closing price. On the day, 1.93 million shares were traded. CTMX stock price reached its highest trading level at $2.39 during the session, while it also had its lowest trading level at $2.155.
Ratios:
For a deeper understanding of CytomX Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.73 and its Current Ratio is at 1.73. In the meantime, Its Debt-to-Equity ratio is 0.33 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Oppenheimer on July 31, 2025, initiated with a Outperform rating and assigned the stock a target price of $7.
On May 15, 2025, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $5.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 16 ’25 when Ogden Christopher sold 10,614 shares for $2.69 per share. The transaction valued at 28,540 led to the insider holds 226,271 shares of the business.
Ogden Christopher sold 1,641 shares of CTMX for $4,841 on Jun 13 ’25. The Chief Financial Officer now owns 199,385 shares after completing the transaction at $2.95 per share. On Jun 16 ’25, another insider, BELVIN MARCIA, who serves as the SVP, Chief Scientific Officer of the company, sold 13,884 shares for $2.69 each. As a result, the insider received 37,334 and left with 272,252 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTMX now has a Market Capitalization of 341870496 and an Enterprise Value of 103211208. As of this moment, CytomX’s Price-to-Earnings (P/E) ratio for their current fiscal year is 4.38. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.32 while its Price-to-Book (P/B) ratio in mrq is 6.98. Its current Enterprise Value per Revenue stands at 0.699 whereas that against EBITDA is 2.742.
Stock Price History:
The Beta on a monthly basis for CTMX is 2.18, which has changed by 0.83898306 over the last 52 weeks, in comparison to a change of 0.19283521 over the same period for the S&P500. Over the past 52 weeks, CTMX has reached a high of $3.10, while it has fallen to a 52-week low of $0.40. The 50-Day Moving Average of the stock is -10.25%, while the 200-Day Moving Average is calculated to be 64.65%.
Shares Statistics:
For the past three months, CTMX has traded an average of 5.01M shares per day and 1421010 over the past ten days. A total of 157.54M shares are outstanding, with a floating share count of 130.57M. Insiders hold about 17.12% of the company’s shares, while institutions hold 34.22% stake in the company. Shares short for CTMX as of 1752537600 were 23869489 with a Short Ratio of 4.77, compared to 1749772800 on 20791019. Therefore, it implies a Short% of Shares Outstanding of 23869489 and a Short% of Float of 15.740000000000002.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Current recommendations for the stock of the company come from 6.0 analysts. The consensus estimate for the next quarter is -$0.07, with high estimates of $0.02 and low estimates of -$0.12.
Analysts are recommending an EPS of between $0.23 and -$0.22 for the fiscal current year, implying an average EPS of -$0.08. EPS for the following year is -$0.44, with 7.0 analysts recommending between -$0.01 and -$0.7.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $18.28M this quarter.It ranges from a high estimate of $30M to a low estimate of $4M. As of the current estimate, CytomX Therapeutics Inc’s year-ago sales were $25.11MFor the next quarter, 5 analysts are estimating revenue of $15.9M. There is a high estimate of $30M for the next quarter, whereas the lowest estimate is $4M.
A total of 6 analysts have provided revenue estimates for CTMX’s current fiscal year. The highest revenue estimate was $140.92M, while the lowest revenue estimate was $62.92M, resulting in an average revenue estimate of $98.28M. In the same quarter a year ago, actual revenue was $138.1MBased on 6 analysts’ estimates, the company’s revenue will be $56.81M in the next fiscal year. The high estimate is $120M and the low estimate is $4M.
